Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Common Equity (2021 - 2025)

Historic Common Equity for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Common Equity rose 2845.08% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2845.08%. This contributed to the annual value of $946.4 million for FY2024, which is 2154.25% up from last year.
  • Per Krystal Biotech's latest filing, its Common Equity stood at $1.1 billion for Q3 2025, which was up 2845.08% from $1.0 billion recorded in Q2 2025.
  • Krystal Biotech's Common Equity's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $408.2 million in Q3 2021.
  • For the 5-year period, Krystal Biotech's Common Equity averaged around $701.7 million, with its median value being $653.1 million (2023).
  • In the last 5 years, Krystal Biotech's Common Equity plummeted by 1201.95% in 2022 and then skyrocketed by 6325.52% in 2024.
  • Over the past 5 years, Krystal Biotech's Common Equity (Quarter) stood at $593.6 million in 2021, then fell by 12.02% to $522.2 million in 2022, then skyrocketed by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then grew by 20.23% to $1.1 billion in 2025.
  • Its Common Equity was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $984.7 million in Q1 2025.